Sustained-release nanoART formulation for the treatment of neuroAIDS

Rahul Dev Jayant, Venkata SR Atluri, Marisela Agudelo, Vidya Sagar, Ajeet Kaushik, Madhavan Nair Center for Personalized Nanomedicine, Department of Immunology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA Abstract: A novel approach was developed...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Jayant RD, Atluri VSR, Agudelo M, Sagar V, Kaushik A, Nair M
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://doaj.org/article/e761759b94eb4c9daff870628ac27214
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:e761759b94eb4c9daff870628ac27214
record_format dspace
spelling oai:doaj.org-article:e761759b94eb4c9daff870628ac272142021-12-02T05:04:29ZSustained-release nanoART formulation for the treatment of neuroAIDS1178-2013https://doaj.org/article/e761759b94eb4c9daff870628ac272142015-02-01T00:00:00Zhttp://www.dovepress.com/sustained-release-nanoart-formulation-for-thenbsptreatment-of-neuroaid-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013 Rahul Dev Jayant, Venkata SR Atluri, Marisela Agudelo, Vidya Sagar, Ajeet Kaushik, Madhavan Nair Center for Personalized Nanomedicine, Department of Immunology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA Abstract: A novel approach was developed for the coencapsulation of an anti-HIV drug (tenofovir) and a latency-breaking agent (vorinostat), using magnetically guided layer-by-layer (LbL) assembled nanocarriers for the treatment of neuroAIDS. Ultrasmall iron oxide (Fe3O4) nanoparticles (10±3 nm) were synthesized and characterized. The LbL technique was used to achieve a sustained release profile, and application of 2 bilayers ([tenofovir+dextran sulphate]2+vorinostat) to magnetic nanoparticles resulted in a 2.8 times increase in drug (tenofovir) loading and also resulted in an increase in the drug release period by 30-fold, with 100% drug release in sustained manner over a period of 5 days with the simultaneous stimulation of latent HIV expression. Nanoformulation showed a good blood–brain barrier transmigration ability (37.95%±1.5%) with good in vitro antiviral efficacy (~33% reduction of p24 level) over a period of 5 days after HIV infection in primary human astrocytes, with good cell viability (>90%). Hence, LbL arrangements of drugs on magnetic nanoparticles provides sustained release and, therefore, may improve the patient’s adherence to therapy and lead to better compliance. Keywords: layer-by-layer, magnetic nanocarriers, blood–brain barriers, neuroAIDS, sustained release, anti-HIV drug, latencyJayant RDAtluri VSRAgudelo MSagar VKaushik ANair MDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2015, Iss default, Pp 1077-1093 (2015)
institution DOAJ
collection DOAJ
language EN
topic Medicine (General)
R5-920
spellingShingle Medicine (General)
R5-920
Jayant RD
Atluri VSR
Agudelo M
Sagar V
Kaushik A
Nair M
Sustained-release nanoART formulation for the treatment of neuroAIDS
description Rahul Dev Jayant, Venkata SR Atluri, Marisela Agudelo, Vidya Sagar, Ajeet Kaushik, Madhavan Nair Center for Personalized Nanomedicine, Department of Immunology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA Abstract: A novel approach was developed for the coencapsulation of an anti-HIV drug (tenofovir) and a latency-breaking agent (vorinostat), using magnetically guided layer-by-layer (LbL) assembled nanocarriers for the treatment of neuroAIDS. Ultrasmall iron oxide (Fe3O4) nanoparticles (10±3 nm) were synthesized and characterized. The LbL technique was used to achieve a sustained release profile, and application of 2 bilayers ([tenofovir+dextran sulphate]2+vorinostat) to magnetic nanoparticles resulted in a 2.8 times increase in drug (tenofovir) loading and also resulted in an increase in the drug release period by 30-fold, with 100% drug release in sustained manner over a period of 5 days with the simultaneous stimulation of latent HIV expression. Nanoformulation showed a good blood–brain barrier transmigration ability (37.95%±1.5%) with good in vitro antiviral efficacy (~33% reduction of p24 level) over a period of 5 days after HIV infection in primary human astrocytes, with good cell viability (>90%). Hence, LbL arrangements of drugs on magnetic nanoparticles provides sustained release and, therefore, may improve the patient’s adherence to therapy and lead to better compliance. Keywords: layer-by-layer, magnetic nanocarriers, blood–brain barriers, neuroAIDS, sustained release, anti-HIV drug, latency
format article
author Jayant RD
Atluri VSR
Agudelo M
Sagar V
Kaushik A
Nair M
author_facet Jayant RD
Atluri VSR
Agudelo M
Sagar V
Kaushik A
Nair M
author_sort Jayant RD
title Sustained-release nanoART formulation for the treatment of neuroAIDS
title_short Sustained-release nanoART formulation for the treatment of neuroAIDS
title_full Sustained-release nanoART formulation for the treatment of neuroAIDS
title_fullStr Sustained-release nanoART formulation for the treatment of neuroAIDS
title_full_unstemmed Sustained-release nanoART formulation for the treatment of neuroAIDS
title_sort sustained-release nanoart formulation for the treatment of neuroaids
publisher Dove Medical Press
publishDate 2015
url https://doaj.org/article/e761759b94eb4c9daff870628ac27214
work_keys_str_mv AT jayantrd sustainedreleasenanoartformulationforthenbsptreatmentofneuroaids
AT atlurivsr sustainedreleasenanoartformulationforthenbsptreatmentofneuroaids
AT agudelom sustainedreleasenanoartformulationforthenbsptreatmentofneuroaids
AT sagarv sustainedreleasenanoartformulationforthenbsptreatmentofneuroaids
AT kaushika sustainedreleasenanoartformulationforthenbsptreatmentofneuroaids
AT nairm sustainedreleasenanoartformulationforthenbsptreatmentofneuroaids
_version_ 1718400684218384384